Altimmune ALT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$22.56M+17.5% | -$27.36M-43.9% | -$19.01M+14.1% | -$22.15M-13.1% | -$19.58M+15.6% | ||
| $23K-11.5% | $26K-3.7% | $27K-10.0% | $30K+3.4% | $29K-12.1% | ||
| $3.38M-31.6% | $4.94M+39.0% | $3.55M-0.3% | $3.57M-11.2% | $4.02M+19.7% | ||
| —— | —— | —— | —— | -$681K— | ||
| $218K+13.5% | $192K+69.9% | $113K— | —— | —— | ||
| $709K— | —— | —— | —— | —— | ||
| $446K+19.3% | $374K-28.6% | $524K+382% | -$186K-403% | -$37K— | ||
| -$1.19M— | —— | $3.95M— | —— | $866K+194% | ||
| -$2.49M-157% | $4.35M+4,166% | $102K+128% | -$365K+78.5% | -$1.7M— | ||
| -$1.62M— | —— | $8K-99.5% | $1.47M+243% | $428K+154% | ||
| -$20.94M-7.7% | -$19.45M-63.5% | -$11.9M+38.5% | -$19.35M-14.9% | -$16.84M+7.8% | ||
| $21K+2,000% | $1K— | —— | —— | —— | ||
| $43.29M-51.1% | $88.55M-40.7% | $149.32M+3,269% | $4.43M-89.7% | $43.14M+227% | ||
| $39.62M+322% | $9.4M— | $0-100% | $105.55M+177% | $38.04M+41.7% | ||
| -$3.69M+95.3% | -$79.16M+47.0% | -$149.32M-248% | $101.11M+2,082% | -$5.1M— | ||
| $8.74M-85.8% | $61.65M+56.0% | $39.52M+4.5% | $37.82M+8.8% | $34.75M+260% | ||
| $695K+2,680% | $25K— | $0-100% | $6K-99.1% | $678K+33,800% | ||
| —— | —— | —— | —— | $4K— | ||
| $78.47M-3.3% | $81.13M+106% | $39.35M-24.7% | $52.24M+53.1% | $34.12M+238% | ||
| -$154K-250% | -$44K+48.8% | -$86K-91.1% | -$45K-400% | $15K-87.2% | ||
| $53.84M— | —— | —— | $134M+1,000% | $12.18M— | ||
| $849K+64.9% | $515K+35.2% | $381K— | —— | —— | ||
| $870K-4.5% | $911K+365% | $196K-54.5% | $431K-37.2% | $686K-16.2% | ||
| $218K+13.5% | $192K+69.9% | $113K— | —— | —— | ||
| $23K-11.5% | $26K-3.7% | $27K-10.0% | $30K+3.4% | $29K-12.1% | ||
| $709K— | —— | —— | —— | —— | ||
| -$2.49M-157% | $4.35M+4,166% | $102K+128% | -$365K+78.5% | -$1.7M— | ||
| -$518K-1,686% | -$29K-190% | -$10K+99.3% | -$1.4M-7.9% | -$1.3M-283% | ||
| -$1.62M— | —— | $8K-99.5% | $1.47M+243% | $428K+154% | ||
| $39.62M+322% | $9.4M— | $0-100% | $105.55M+177% | $38.04M+41.7% | ||
| $89K-36.4% | $140K— | $0-100% | $173K+38.4% | $125K— | ||
| $70.34M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $4K— | ||
| $177K— | —— | $121K— | —— | $170K— | ||
| —— | —— | —— | —— | $173K— | ||
| -$20.96M-7.8% | -$19.45M-63.5% | -$11.9M— | —— | —— | ||
| -$20.96M-7.8% | -$19.45M-63.5% | -$11.9M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Altimmune generate?
- Altimmune (ALT) generated -$71.6M in operating cash flow over the trailing twelve months.
- What is Altimmune's free cash flow?
- After $111.0K of capital expenditures, Altimmune's free cash flow was -$68.8M over the trailing twelve months, up 10.2% year over year.
- Where does Altimmune's cash flow data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
